MitoQ Review: What the Human Evidence Actually Shows

Edited by Samael A. Tejada, Founder & Editor-in-Chief

MitoQ is the rare supplement with a genuinely clever idea behind it and a real — if thin — human trial record. It is also sold with the confidence of a proven therapy, which the record does not support. This review goes through the human evidence trial by trial: what was tested, in whom, at what dose, and what actually happened. MyMitochondria is an independent publication: we are not affiliated with MitoQ Ltd, we do not sell MitoQ, and nothing here is medical advice.

What is MitoQ, and how is it different from regular CoQ10?

MitoQ's active ingredient is mitoquinone (sold on the label as mitoquinol mesylate). Chemically, it is the same antioxidant head as coenzyme Q10 — a ubiquinone — with one decisive modification: a positively charged tail called triphenylphosphonium (TPP+) bolted on. Mitochondria carry a strong negative charge inside, so the TPP+ tail drags the molecule across the mitochondrial membrane and concentrates it inside, several hundred-fold in preclinical work. Regular CoQ10 has no such targeting: most of an oral dose never reaches the inside of a mitochondrion at all.

The molecule was developed in the late 1990s at the University of Otago in New Zealand by biochemists Michael Murphy and Robin Smith, specifically to fix CoQ10's delivery problem. It was first developed as a drug — it went through phase II trials in Parkinson's disease and hepatitis C — and after those trials failed to show clinical benefit, it was remarketed as a dietary supplement by MitoQ Ltd of Auckland, New Zealand. The flagship product, MitoQ Pure, is a bottle of 60 capsules at 5 mg each; the label dose is two capsules — 10 mg — each morning.

That targeting story is real chemistry, and it is the honest core of the product. What it does not establish is that concentrating an antioxidant inside mitochondria improves health outcomes in people. That is a separate question, and only trials can answer it.

Does MitoQ work? The flagship blood-vessel trial

The strongest human result for MitoQ comes from the University of Colorado Boulder. In a randomized, double-blind, placebo-controlled crossover trial published in Hypertension in 2018, 20 healthy adults aged 60 to 79 — all selected because their arteries already dilated poorly (brachial artery flow-mediated dilation under 6%) — took 20 mg of MitoQ a day for six weeks. Flow-mediated dilation, a standard ultrasound measure of how well the artery lining works, was 42% higher after MitoQ than after placebo, and plasma oxidized LDL, a marker of oxidative stress, was lower. Aortic stiffness improved only in the 11 participants who started with the stiffest arteries, and inflammation markers did not change. MitoQ was well tolerated.

Read carefully, this is a genuinely encouraging result with three honest limits. First, 20 people is a pilot-sized sample. Second, flow-mediated dilation is a surrogate — a stand-in measure correlated with cardiovascular risk, not a heart attack, stroke, or death prevented. Third, the dose was 20 mg a day, twice the 10 mg label dose on the bottle the company sells for this purpose. A larger three-month trial of the same dose, run by the same group with 112 people enrolled, has been completed — but its results have not been published, so the flagship finding still rests on one small, short study.

Evidence label: Preliminary — one small crossover trial, positive on a surrogate endpoint, awaiting a published confirmatory trial.

Does MitoQ improve exercise performance?

Two trials from the University of Auckland say: a little, in specific ways. In a 2021 crossover trial, 19 recreationally trained middle-aged male cyclists took 20 mg a day for 28 days and completed an 8 km time trial 1.3% faster on MitoQ than on placebo — about 10 seconds — with 4.4% higher average power and roughly 18% lower levels of a blood marker of exercise-induced oxidative damage. The effect was real but small (an effect size of 0.2, the bottom of 'small'), in 19 men, on one test.

A 2022 trial in untrained middle-aged men doing high-intensity interval training found MitoQ amplified the muscle's PGC-1α signal after exercise — PGC-1α is the master switch for building new mitochondria — and the MitoQ group gained more peak power from training. But VO2peak (overall aerobic capacity) and mitochondrial content did not differ from placebo. In plain terms: MitoQ may sharpen top-end power and blunt exercise oxidative stress slightly; it has not been shown to make you fitter in the broad sense, and one thesis study from the same lab found it delayed recovery of one measure of muscle strength after damaging eccentric exercise.

Evidence label: Preliminary — small trials, small effects, surrogate and performance measures only.

Where MitoQ failed: the Parkinson's and liver trials

Any honest MitoQ review has to give the failures equal billing, because they are the largest and longest trials the molecule has ever had. In 2010, a double-blind trial randomized 128 people with newly diagnosed, untreated Parkinson's disease to 40 mg, 80 mg, or placebo for a full year. MitoQ did not slow disease progression on any measure, including the standard UPDRS rating scale. The authors' conclusion was blunt: MitoQ does not slow the progression of Parkinson's disease. That result ended MitoQ's life as a drug candidate for Parkinson's.

The same year, a phase II trial in 30 people with chronic hepatitis C gave 40 or 80 mg a day for 28 days. Liver enzymes (ALT and AST) fell from where they started in both MitoQ groups — but the day-28 difference against placebo did not reach significance, and the virus itself was completely unaffected. A liver-enzyme nudge that cannot be separated from placebo is not a treatment.

More recent work from the Colorado group on physical function in ageing — strength, mobility, muscle mitochondrial measures — has likewise come back mostly null so far, with at most a possible strength signal in the small subgroup aged 70 and over. The pattern across two decades is consistent: MitoQ demonstrably reaches mitochondria and lowers oxidative-stress markers, and that pharmacology has so far translated into one small positive surrogate result in blood vessels — not into proven clinical benefit for any disease.

How much does MitoQ cost — and what dose did the trials actually use?

At MitoQ's own online store (checked November 1, 2026), MitoQ Pure costs $62.95 for a one-month supply — 60 capsules of 5 mg — or $53.51 a month on a subscribe-and-save plan, with a 90-day money-back guarantee. The label dose is two capsules each morning: 10 mg a day.

Now the part the price page does not tell you. Every positive human trial above — the blood-vessel trial, both cycling trials — used 20 mg a day, double the label dose. Matching the studied dose means four capsules a day, two bottles a month: $125.90 a month at list price, about $1,511 a year. That does not make the product dishonest — 10 mg may do something; it has simply never been the dose shown to do anything in a controlled trial. When you price MitoQ, price the dose the evidence used.

What are MitoQ's side effects? Is it safe?

On the published record, MitoQ is well tolerated. Across its trials — including 80 mg a day for a full year in the Parkinson's study, eight times the label dose — adverse events were generally mild and similar to placebo. The complaints that do appear are gastrointestinal: nausea and stomach upset are the most commonly reported, and the brand itself advises taking it before food in the morning, which some users find helps.

The honest limits: no trial has followed users beyond 12 months, so long-term safety is unstudied rather than proven; safety in pregnancy and breastfeeding is unknown; and MitoQ is sold as a dietary supplement, which means the FDA has not evaluated it for safety or effectiveness the way it would a drug. High-dose antioxidants are not automatically benign — in laboratory work, concentrated MitoQ can act on the respiratory chain itself at high concentrations — which is one more reason 'more' is not a strategy here.

Who should skip MitoQ?

• Anyone hoping to treat a disease. MitoQ did not slow Parkinson's in a year-long trial and is not a treatment for any condition. If a clinician has proposed it as therapy, ask what trial supports that.
• Pregnant or breastfeeding women, and children — there is no safety data at all in these groups.
• People on complex medication regimens — particularly blood thinners or blood-pressure medication — should clear it with their clinician first. CoQ10-family compounds have theoretical interaction potential, and MitoQ's own interaction profile is essentially unstudied.
• Anyone expecting a proven longevity effect. No human trial has measured lifespan, cognition, or disease prevention. If $63 to $126 a month needs a proven return, this is not it yet.

MitoQ vs. CoQ10: which is the better buy?

The case for MitoQ over regular CoQ10 is the targeting: CoQ10 is poorly absorbed and barely reaches the mitochondrial interior, while MitoQ is engineered to concentrate there — and MitoQ owns the single most interesting small vascular trial in this category. The case for CoQ10 is everything else: it costs a fraction as much (a month of reputable ubiquinol typically runs $15 to $40), its human literature is far larger — including a large long-term trial in older adults (Q-SYMBIO) reporting fewer cardiovascular events on CoQ10, a result MitoQ has nothing to match — and our CoQ10 guide grades that evidence in full.

Our read: if you are an older adult specifically interested in the artery finding, can afford the trial dose, and understand it is one small study, MitoQ is a defensible experiment. For everyone else, plain CoQ10 — or neither — is the rational spend today. What neither product has earned is the word 'proven' next to energy, longevity, or disease claims.

The bottom line

MitoQ is a real molecule with a real mechanism and a real — small, short, surrogate-endpoint — human evidence base: one encouraging blood-vessel trial at 20 mg a day, small exercise effects, a clear Parkinson's failure, and a liver result indistinguishable from placebo. It is among the better-studied mitochondrial supplements, which says as much about the category as about MitoQ. Buy it, if you buy it, as a well-characterized experiment on your arteries at the studied dose and price — not as the proven cellular-energy therapy its marketing describes. And if you want to know what your own mitochondria are actually doing before spending on any of this, start with our mitochondrial testing comparison.

Independence note: MyMitochondria is not affiliated with MitoQ Ltd or Antipodean Pharmaceuticals, receives no payment from them, and sells no supplements. MitoQ is a trademark of its owner, used here only to name the product under review. Prices were checked on the maker's own store on November 1, 2026 and change over time.

Where the evidence stands

• Established: MitoQ concentrates inside mitochondria. Its TPP+ tail uses the mitochondrial membrane potential to accumulate the antioxidant several hundred-fold in preclinical work (Smith & Murphy 2010, PMID 20649545).
• Preliminary: MitoQ improves artery function in older adults: one crossover RCT, n=20 aged 60–79 with impaired baseline dilation, 20 mg/day for 6 weeks — flow-mediated dilation 42% higher vs. placebo, oxidized LDL lower; a surrogate endpoint, and the larger 3-month trial (n=112, NCT04851288) is completed but unpublished (Rossman 2018, PMID 29661838).
• Preliminary: Small exercise effects: 8 km cycling time trial 1.3% faster (n=19, 20 mg/day, 28 days; Broome 2021) and greater training-induced peak power with amplified PGC-1α signaling, but no VO2peak difference (Broome 2022).
• Absent: MitoQ slows Parkinson's disease — tested and not found: 128 patients, 40/80 mg/day for 12 months, no difference from placebo on any progression measure (Snow 2010, PMID 20568096).
• Preliminary: Liver protection in hepatitis C: ALT fell from baseline in both dose groups over 28 days (n=30), but the difference vs. placebo was not significant and viral load did not change (Gane 2010, PMID 20492507).
• Absent: Hard outcomes — fewer heart attacks or strokes, better cognition, longer life. No human trial of MitoQ has measured any clinical endpoint of this kind.